Table 2 Summary of toxicity in Trial 1 using the TTK containing vaccine
Vaccine doses | 0.5Â mg (n=3) | 1.0Â mg (n=3) | 3.0Â mg (n=3) | Total patients (n=9) | ||||
|---|---|---|---|---|---|---|---|---|
| Â | Grade | Grade | Grade | (%) | ||||
| Â | 1-2 | 3(4) | 1-2 | 3(4) | 1-2 | 3(4) | Â | Â |
Blood/bone marrow | Â | Â | Â | Â | Â | Â | Â | Â |
   Anemia | 1 | 0 | 1 | 0 | 2 | 0 | 3 | (33%) |
   Leukopenia | 0 | 0 | 1 | 0 | 0 | 0 | 1 | (11%) |
Constitutional symptoms | Â | Â | Â | Â | Â | Â | Â | Â |
   Fatigue | 1 | 0 | 2 | 0 | 1 | 0 | 4 | (44%) |
Gastrointestinal | Â | Â | Â | Â | Â | Â | Â | Â |
   Nausea/vomiting | 0 | 0 | 2 | 0 | 1 | 0 | 3 | (33%) |
   Anorexia | 0 | 1 | 2 | 0 | 0 | 0 | 3 | (33%) |
   Constipation | 0 | 0 | 1 | 0 | 0 | 0 | 1 | (11%) |
Dermatology/skin | Â | Â | Â | Â | Â | Â | Â | Â |
   Rash | 2 | 0 | 2 | 0 | 3 | 0 | 7 | (77%) |
   Pruritus | 0 | 0 | 1 | 0 | 2 | 0 | 3 | (33%) |
   Reaction at the injection site | 2 | 0 | 2 | 0 | 3 | 0 | 7 | (77%) |